Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06216899 · ClinicalTrials.gov registry record · NA

Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial

A NA study of Crohn Disease, sponsored by Seattle Children's Hospital.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
3
Study locations

NCT06216899: Recruiting NA study of Crohn Disease, sponsored by Seattle Children's Hospital.

NCT06216899 is a NA study of Crohn Disease that is actively recruiting participants, run by Seattle Children's Hospital. The registered enrollment target is 60 participants, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (71% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06216899, a NA study of Crohn Disease, is actively recruiting participants, sponsored by Seattle Children's Hospital.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
3
Study locations

Study Summary

This study will compare the tolerability and efficacy of conventional formula Exclusive Enteral Nutrition (EEN) and whole-food blended smoothie EEN by enrolling a total of 60 participants with newly diagnosed pediatric Crohn's disease (CD). Participants will be provided either commercial formula or guided on the preparation of the home-blended smoothie. These participants will be given a specific recipe, blender, and be provided the food components to the smoothie. The study will total 8 weeks and will assess tolerance, clinical outcomes, stool microbiome, and quality of life.

Primary Outcome

Tolerance of therapy as measured by ability to continue prescribed nutritional therapy over 4-weeks and 8-weeks without deviation from protocol. Participants will meet with a study dietitian at week 2, week4, and week 8. Dietitians will evaluate caloric needs, specific deficits, and dietary limitations.

Conditions Studied

Interventions

  • OTHER Whole-food based smoothie
  • OTHER Formula

Study Locations (3)

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia

Washington

  • Seattle Children's Hospital - Seattle

Nova Scotia

  • Izaak Walton Killam Health Centre - Halifax

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-03-11
Est. Completion 2030-01-10
Phase NA
Seattle Children's Hospital

168 total trials

What NCT06216899 shows while recruiting

NCT06216899 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (71% lower).

The record links to 1 condition, with Crohn Disease appearing as the primary indexed condition, and to 2 interventions - of which Whole-food based smoothie is the first listed.

NCT06216899 reports a single indexed study location in Pennsylvania, Washington, Nova Scotia.

Frequently Asked Questions

What is clinical trial NCT06216899 about?

NCT06216899 is a clinical study titled "Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial". This study will compare the tolerability and efficacy of conventional formula Exclusive Enteral Nutrition (EEN) and whole-food blended smoothie EEN by enrolling a total of 60 participants with newly diagnosed pediatric Crohn's disease (CD). Participants will be provided either commercial formula or...

What is the current status of trial NCT06216899?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2024-03-11. Estimated completion is 2030-01-10.

What conditions does trial NCT06216899 study?

This clinical trial studies the following conditions: Crohn Disease.

What interventions are being tested in trial NCT06216899?

The interventions under investigation include: Whole-food based smoothie (OTHER), Formula (OTHER).

Who is sponsoring clinical trial NCT06216899?

This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06216899 being conducted?

This trial has 3 study locations across Pennsylvania, Washington, Nova Scotia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Crohn Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06216899's enrollment target sits among peer trials

60 43rd of 71 higher than 28 of 71 other Crohn Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Crohn Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06216899, the US trial registry maintained by the National Library of Medicine. NCT06216899 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.